Reply to the Harry Herr's Letter to the Editor re: Oscar Buisan, Pol Servian, Sonia Pedreño-Lopez, et al. A Novel Heterologous Prime-boost Strategy Using RUTI Vaccine to Improve the Bacillus Calmette-Guérin Response in Non-muscle-invasive Bladder Cancer Patients: Phase 1 RUTIVAC-1 Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2025 [0.03%]
Harry Herr关于Oscar Buisan、Pol Servian、Sonia Pedreño-Lopez等人信件的回复：一项新颖的异源prime-boost策略，使用RUTI疫苗改善非肌层浸润性膀胱癌患者卡介苗治疗反应：RUTIVAC-1期试验。Eur Urol. 在线发表。https://doi.org/10.1016/j.eururo.2025
Cecilia Cabrera,Oscar Buisan,Pol Servian
Cecilia Cabrera
Reconstruction of a Devastated Ureter: Multi-institutional Experience with Robotic Intracorporeal Ileal Ureter Replacement [0.03%]
机器人辅助回肠代输尿管术重建毁损性输尿管的多中心经验
Emily Ji,Aurash Naser-Tavakolian,Diboro Kanabolo et al.
Emily Ji et al.
Background and objective: To report our multi-institutional outcomes with robotic intracorporeal ileal ureter replacement (RIUR). Methods: ...
Active Surveillance Versus Intravesical Bacillus Calmette-Guérin for High-grade T1 Bladder Cancer with Negative Second Transurethral Resection: The Randomized Noninferiority Phase 3 JCOG1019 Trial [0.03%]
高分级T1期膀胱癌患者第2次经尿道切除术阴性后的主动监测与卡介苗灌注的非劣效性III期临床研究（JCOG1019）
Hiroshi Kitamura,Taiji Tsukamoto,Yoshiyuki Kakehi et al.
Hiroshi Kitamura et al.
Background and objective: We evaluated the noninferiority of active surveillance (AS) in comparison to intravesical bacillus Calmette-Guérin (BCG) in terms of recurrence and progression for patients with high-grade T1 (H...
Targeting Prostatic Acid Phosphatase in Prostate Cancer: Roadmap on How To Venture Above and Beyond Prostate-specific Membrane Antigen with ACP3 Theranostics [0.03%]
靶向前列腺酸性磷酸酶治疗前列腺癌：ACP3诊疗策略在前列腺特异性膜抗原之后的路线图
Cristiano Pini,Fabrizia Gelardi,Martina Sollini et al.
Cristiano Pini et al.
Re: Maria De Santis, Joan Palou Redorta, Hiroyuki Nishiyama, et al. Durvalumab in Combination with BCG for BCG-naive, High-risk, Non-muscle-invasive Bladder Cancer (POTOMAC): Final Analysis of a Randomised, Open-label, Phase 3 trial. Lancet 2025;406:2221-34 [0.03%]
Nishiyama N, Palou-Jimenez R, Guo C, et al. Durvalumab联合BCG治疗高危、非肌层浸润性膀胱癌（POTOMAC研究）：一项随机、开放标签、III期试验的最终分析. 2025;406:2221-34
Tyler S Garman,Max R Kates
Tyler S Garman
Regional Node-positive Bladder Cancer: Therapeutic Decisions Based on Trial Results in Perioperative and Advanced Disease Settings [0.03%]
区域淋巴结阳性膀胱癌：基于围手术期和晚期疾病设置的试验结果制定治疗决策
Renate Pichler,José Daniel Subiela,Pietro Scilipoti et al.
Renate Pichler et al.
Optimal therapeutic management for cN1 M0 bladder cancer consists of perioperative systemic therapy and radical cystectomy. For patients with cN2-3 M0 disease, evidence supports upfront systemic therapy, preferably with enfortumab vedotin +...
Bladder Preservation Therapy in Combination with Atezolizumab and Radiation Therapy (BPT-ART) for Invasive Bladder Cancer: Final Analysis from a Multicentre, Open-label, Prospective Phase 2 Trial [0.03%]
联合阿特朱单抗和放疗的膀胱保留疗法(BPT-ART)治疗侵袭性膀胱癌：一项多中心、开放标签、前瞻性Ⅱ期试验的最终分析
Yoshiyuki Nagumo,Tomokazu Kimura,Hitoshi Ishikawa et al.
Yoshiyuki Nagumo et al.
Radical cystectomy (RC) is the standard care for muscle-invasive or very high-risk non-muscle-invasive bladder cancer (BC), but optimal management for bladder preservation remains uncertain. In this multicentre, open-label, phase 2 trial, p...
Re: Primary Retroperitoneal Lymph Node Dissection in Marker Positive Clinical Stage II Non-Seminomatous Germ Cell Tumours [0.03%]
标志物阳性的临床二期非精原细胞瘤的一期后腹膜淋巴结清扫术的再思考
Benjamin Baker,Sarah Azari,Margaret Meagher et al.
Benjamin Baker et al.
The Discovery of Prostate-specific Membrane Antigen Ligands: The Long Road to Changes in Clinical Practice for Prostate Cancer [0.03%]
前列腺特异性膜抗原配体的发现：前列腺癌临床实践变革的漫长之路
Martina Benešová-Schäfer,Uwe Haberkorn,John W Babich
Martina Benešová-Schäfer
Prostate-specific membrane antigen (PSMA)-targeting strategies in prostate cancer have evolved rapidly from early antibody-based approaches to highly effective diagnostic and therapeutic agents. While PSMA remains a central benchmark in met...